|
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
110 cases of MCL have been analysed for their cytomorphological features, mitotic and proliferation indices, bcl-1 rearrangements, p53 expression patterns and DNA content by both interphase cytogenetic as well as DNA flow cytometric analyses.
|
10037001 |
1998 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mantle cell lymphoma cell lines with known p53 status were treated with GUT-70, a tricyclic coumarin derived from Calophyllum brasiliense, and the biological and biochemical consequences of GUT-70 were studied.
|
21139584 |
2011 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutation was insufficiently an independent prognostic factor in patients with MCL at advanced stage.
|
22057359 |
2012 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53 alterations are strongly associated with a high proliferation index and aggressive behavior in mantle cell lymphoma.
|
22315488 |
2012 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
|
30146365 |
2018 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53 was mutated in 13/63 (21%) cases, including 5/7 (71%) leukemic non-nodal and 8/56 (14%) conventional mantle cell lymphoma.
|
31296581 |
2020 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A high incidence of p53 gene alterations was found, almost equivalent in aCLL and MCL.
|
10980628 |
2000 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.
|
30537212 |
2019 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Applying LOH analysis in 52 MCL patient samples, we confirmed frequent alterations in 9p21 (28.6%) and p53 (28.9%) but also detected allelic losses in 1p21, 9q21, 13q13-14, 13q31-32, 17p13.1, and 17p13.3 in 28-45% of cases and allelic gains in 3q27-28 and 19p13.3 in 14-22% of cases.
|
19137297 |
2009 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
|
30626249 |
2019 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Backtracking analysis using quantitative PCR specifically detecting an MCL-restricted focal deletion of TP53 revealed that the pre-MCL clone appeared in the bone marrow and peripheral blood of the patient approximately 4 years before the clinical manifestation of MCL.
|
27407063 |
2016 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Blastoid MCL subtypes were characterized by distinctly elevated mitotic counts (57 and 51/10 HPF v 21/10 high-power fields in common MCL), proliferation indices (58% and 53% v 27% in common types, respectively; P < .001), frequent bcl-1 rearrangements at the major translocation cluster locus (59% v 40%), and overexpression of p53 (21% v 6%).
|
9028966 |
1997 |
|
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Chromosome 17 abnormalities are common in leukemic MCL, may be involved in pathogenesis, and are associated with p53 expression.
|
11706075 |
2001 |
|
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Correlation of MCL p53 and p27 expression with clinical data showed an association between reduced overall survival rates and the overexpression of p53 (P =.001), the loss of p27 (P =.002), or both.
|
10627471 |
2000 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cryptic and complex chromosomal rearrangements and the deletion of TP53 gene in a patient with leukemic mantle cell lymphoma.
|
16938577 |
2006 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deletion and mutation, usually associated, of ATM or TP53 are frequent in Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma.
|
28284458 |
2017 |
|
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Deletions of chromosome 17p were identified in 2 of 30 cases, both of which were MCLs showing p53 overexpression.
|
7579380 |
1995 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Demonstration of TP53 and NSD2 mutations in patients who developed blastoid transformation and ATM and TP53 mutations in patients who progressed, opens the door for future investigations in ibrutinib-refractory MCL.
|
30175400 |
2018 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite immunochemotherapy, high-dose cytarabine, and ASCT, younger MCL patients with deletions of CDKN2A (p16) and TP53 show an unfavorable prognosis and are candidates for alternative therapeutic strategies.
|
26022239 |
2015 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
From these findings and from data available in the literature the conclusion can be drawn that p53 gene mutations at codons 158 and 167 may be associated with lymphoproliferative disorders and that low- or intermediate-grade NHL, including leukemic mantle cell lymphoma, may frequently carry this genetic change.
|
8603336 |
1996 |
|
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, no mutations were detected in exons 5-9 in this case. p53 expression was also detected in 10% of the cells in an additional large cell type of MCL and in less than 1% of the cells in 6 typical cases.
|
8605352 |
1996 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, GeneChip analyses identified different genes, encoding proteins involved in microtubule dynamics, such as MAP2, MAP6 and TP53, as targets for chromosomal aberration in MCL.
|
19016712 |
2009 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Loss of 17p and gain of 3q, known to be associated with disease progression in MCL, were detected with M-FISH and confirmed with the use of p53 and BCL6 probes together with comparative genomic hybridization, which detected also an interstitial deletion on 7p21.
|
15381376 |
2004 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
|
20850924 |
2010 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MDM4, the newly discovered modulator of p53 protein, is frequently amplified in various solid tumors such as cutaneous melanoma, retinoblastoma and hematological malignances such as chronic lymphocytic leukemia, acute myeloid leukemia and mantle cell lymphoma.
|
26567881 |
2015 |